IONIS PHARMACEUTICALS INC (IONS) Stock Fundamental Analysis

NASDAQ:IONS • US4622221004

83.15 USD
+0.01 (+0.01%)
At close: Feb 20, 2026
83.059 USD
-0.09 (-0.11%)
After Hours: 2/20/2026, 6:54:26 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Taking everything into account, IONS scores 3 out of 10 in our fundamental rating. IONS was compared to 521 industry peers in the Biotechnology industry. IONS has a bad profitability rating. Also its financial health evaluation is rather negative. IONS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • IONS had negative earnings in the past year.
  • IONS had a negative operating cash flow in the past year.
  • In the past 5 years IONS always reported negative net income.
  • In multiple years IONS reported negative operating cash flow during the last 5 years.
IONS Yearly Net Income VS EBIT VS OCF VS FCFIONS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M

1.2 Ratios

  • With an excellent Return On Assets value of -8.45%, IONS belongs to the best of the industry, outperforming 85.22% of the companies in the same industry.
  • With a decent Return On Equity value of -41.48%, IONS is doing good in the industry, outperforming 70.06% of the companies in the same industry.
Industry RankSector Rank
ROA -8.45%
ROE -41.48%
ROIC N/A
ROA(3y)-12.67%
ROA(5y)-11.54%
ROE(3y)-72.98%
ROE(5y)-56.49%
ROIC(3y)N/A
ROIC(5y)N/A
IONS Yearly ROA, ROE, ROICIONS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60 -80

1.3 Margins

  • The Gross Margin of IONS (98.78%) is better than 98.27% of its industry peers.
  • In the last couple of years the Gross Margin of IONS has remained more or less at the same level.
  • IONS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 98.78%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.08%
GM growth 5Y-0.24%
IONS Yearly Profit, Operating, Gross MarginsIONS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • IONS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for IONS has been increased compared to 1 year ago.
  • IONS has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, IONS has an improved debt to assets ratio.
IONS Yearly Shares OutstandingIONS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
IONS Yearly Total Debt VS Total AssetsIONS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

  • IONS has an Altman-Z score of 2.89. This is not the best score and indicates that IONS is in the grey zone with still only limited risk for bankruptcy at the moment.
  • The Altman-Z score of IONS (2.89) is better than 67.37% of its industry peers.
  • A Debt/Equity ratio of 1.85 is on the high side and indicates that IONS has dependencies on debt financing.
  • The Debt to Equity ratio of IONS (1.85) is worse than 77.93% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.85
Debt/FCF N/A
Altman-Z 2.89
ROIC/WACCN/A
WACC8.02%
IONS Yearly LT Debt VS Equity VS FCFIONS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B

2.3 Liquidity

  • A Current Ratio of 2.79 indicates that IONS has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 2.79, IONS is doing worse than 66.60% of the companies in the same industry.
  • A Quick Ratio of 2.78 indicates that IONS has no problem at all paying its short term obligations.
  • IONS has a Quick ratio of 2.78. This is in the lower half of the industry: IONS underperforms 64.49% of its industry peers.
Industry RankSector Rank
Current Ratio 2.79
Quick Ratio 2.78
IONS Yearly Current Assets VS Current LiabilitesIONS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • IONS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 30.74%, which is quite impressive.
  • The Revenue has grown by 20.41% in the past year. This is a very strong growth!
  • The Revenue has been decreasing by -8.88% on average over the past years.
EPS 1Y (TTM)30.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.79%
Revenue 1Y (TTM)20.41%
Revenue growth 3Y-4.54%
Revenue growth 5Y-8.88%
Sales Q2Q%17.16%

3.2 Future

  • The Earnings Per Share is expected to grow by 27.59% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 32.80% on average over the next years. This is a very strong growth
EPS Next Y24.14%
EPS Next 2Y-1.41%
EPS Next 3Y14.92%
EPS Next 5Y27.59%
Revenue Next Year45.11%
Revenue Next 2Y20.78%
Revenue Next 3Y29.93%
Revenue Next 5Y32.8%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IONS Yearly Revenue VS EstimatesIONS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B 4B 5B
IONS Yearly EPS VS EstimatesIONS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 10

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • IONS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IONS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IONS Price Earnings VS Forward Price EarningsIONS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IONS Per share dataIONS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

  • IONS's earnings are expected to grow with 14.92% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.41%
EPS Next 3Y14.92%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • IONS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IONIS PHARMACEUTICALS INC

NASDAQ:IONS (2/20/2026, 6:54:26 PM)

After market: 83.059 -0.09 (-0.11%)

83.15

+0.01 (+0.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-17
Earnings (Next)04-28
Inst Owners106.67%
Inst Owner Change-9.92%
Ins Owners0.72%
Ins Owner Change-0.01%
Market Cap13.47B
Revenue(TTM)966.96M
Net Income(TTM)-256.34M
Analysts81.38
Price Target91.14 (9.61%)
Short Float %9.68%
Short Ratio7.58
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)147.99%
Min EPS beat(2)36.42%
Max EPS beat(2)259.57%
EPS beat(4)4
Avg EPS beat(4)89.18%
Min EPS beat(4)18.36%
Max EPS beat(4)259.57%
EPS beat(8)8
Avg EPS beat(8)66.23%
EPS beat(12)11
Avg EPS beat(12)44.13%
EPS beat(16)14
Avg EPS beat(16)62.35%
Revenue beat(2)2
Avg Revenue beat(2)33.86%
Min Revenue beat(2)17.57%
Max Revenue beat(2)50.14%
Revenue beat(4)4
Avg Revenue beat(4)33.17%
Min Revenue beat(4)3.26%
Max Revenue beat(4)61.73%
Revenue beat(8)7
Avg Revenue beat(8)31.12%
Revenue beat(12)10
Avg Revenue beat(12)23.51%
Revenue beat(16)13
Avg Revenue beat(16)22.62%
PT rev (1m)4.46%
PT rev (3m)17.89%
EPS NQ rev (1m)0.16%
EPS NQ rev (3m)-1.98%
EPS NY rev (1m)-0.05%
EPS NY rev (3m)2.23%
Revenue NQ rev (1m)3.49%
Revenue NQ rev (3m)3.97%
Revenue NY rev (1m)0.1%
Revenue NY rev (3m)1.44%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 13.93
P/FCF N/A
P/OCF N/A
P/B 21.79
P/tB 21.79
EV/EBITDA N/A
EPS(TTM)-1.69
EYN/A
EPS(NY)-3.13
Fwd EYN/A
FCF(TTM)-1.87
FCFYN/A
OCF(TTM)-1.53
OCFYN/A
SpS5.97
BVpS3.82
TBVpS3.82
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -8.45%
ROE -41.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 98.78%
FCFM N/A
ROA(3y)-12.67%
ROA(5y)-11.54%
ROE(3y)-72.98%
ROE(5y)-56.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.08%
GM growth 5Y-0.24%
F-Score5
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 1.85
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1473.37%
Cap/Sales 5.76%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.79
Quick Ratio 2.78
Altman-Z 2.89
F-Score5
WACC8.02%
ROIC/WACCN/A
Cap/Depr(3y)219.39%
Cap/Depr(5y)190.33%
Cap/Sales(3y)4.04%
Cap/Sales(5y)3.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.79%
EPS Next Y24.14%
EPS Next 2Y-1.41%
EPS Next 3Y14.92%
EPS Next 5Y27.59%
Revenue 1Y (TTM)20.41%
Revenue growth 3Y-4.54%
Revenue growth 5Y-8.88%
Sales Q2Q%17.16%
Revenue Next Year45.11%
Revenue Next 2Y20.78%
Revenue Next 3Y29.93%
Revenue Next 5Y32.8%
EBIT growth 1Y24.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year34.72%
EBIT Next 3Y21.55%
EBIT Next 5YN/A
FCF growth 1Y46.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y54.31%
OCF growth 3YN/A
OCF growth 5YN/A

IONIS PHARMACEUTICALS INC / IONS FAQ

What is the fundamental rating for IONS stock?

ChartMill assigns a fundamental rating of 3 / 10 to IONS.


What is the valuation status of IONIS PHARMACEUTICALS INC (IONS) stock?

ChartMill assigns a valuation rating of 0 / 10 to IONIS PHARMACEUTICALS INC (IONS). This can be considered as Overvalued.


What is the profitability of IONS stock?

IONIS PHARMACEUTICALS INC (IONS) has a profitability rating of 3 / 10.


What is the financial health of IONIS PHARMACEUTICALS INC (IONS) stock?

The financial health rating of IONIS PHARMACEUTICALS INC (IONS) is 3 / 10.